Results of the German IPEP study evaluating the tolerability, efficacy, and acceptance of fulvestrant (FASLODEX (R)) under routine clinical conditions in advanced breast cancer
Dokumenttyp:
Meeting Abstract
Autor(en):
Warm, M; Thomas, A; Ziegler, K; Kates, R; Overkamp, F; Harbeck, N